Literature DB >> 33099421

Systemic Amyloidosis due to Low-Grade Lymphoma.

Ashutosh D Wechalekar1, Raj Chakraborty2, Suzanne Lentzsch3.   

Abstract

Lymphoma-related amyloidosis is a rare entity. Systemic AL amyloidosis is generally caused by an underlying plasma cell clone in the bone marrow with an intact monoclonal immunoglobulin G (IgG) or IgA protein. The rarity of the lymphoma-related amyloidosis makes the generation of data in randomized trials and the determination of the optimal treatment almost impossible. Therefore, treatment recommendations discussed here are based on either retrospective or small prospective trials of single centers.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  IgM amyloidosis; Lymphoma-related AL amyloidosis; Rituximab; Waldenstrom macroglobulinemia

Year:  2020        PMID： 33099421     DOI： 10.1016/j.hoc.2020.08.016

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN： 0889-8588            Impact factor:   3.722


  2 in total

1.  Constrictive Pericarditis Revealing Rare Case of ALH Amyloidosis With Underlying Lymphoplasmacytic Lymphoma (Waldenstrom Macroglobulinemia).

Authors:  Vivian V Ho; Jack W O'Sullivan; William J Collins; Errol Ozdalga; Caitlin F Bell; Neil D Shah; Mayil S Krishnam; Michael G Ozawa; Ronald M Witteles
Journal:  JACC Case Rep       Date:  2022-03-02

2.  Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study.

Authors:  Andrew Staron; Luke Zheng; Gheorghe Doros; Lawreen H Connors; Lisa M Mendelson; Tracy Joshi; Vaishali Sanchorawala
Journal:  Blood Cancer J       Date:  2021-08-04       Impact factor: 11.037
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.